Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Andreas Evers, Torsten Haack, M. Lorenz, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 10, pp. 4293-4303
Closed Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller, Christoffer Clemmensen, Brian Finan, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 712-746
Open Access | Times Cited: 163
Glucagon Receptor Signaling and Glucagon Resistance
Lina Janah, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 157
Glucagon Receptor Signaling and Lipid Metabolism
Katrine D. Galsgaard, Jens Pedersen, Filip K. Knop, et al.
Frontiers in Physiology (2019) Vol. 10
Open Access | Times Cited: 153
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials
J. Tillner, Maximilian Posch, Frank Wagner, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 1, pp. 120-128
Open Access | Times Cited: 149
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions
Shaoyong Lu, Jian Zhang
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 1, pp. 24-45
Closed Access | Times Cited: 129
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Nicholas K. Smith, Troy A. Hackett, Aurelio Galli, et al.
Neurochemistry International (2019) Vol. 128, pp. 94-105
Open Access | Times Cited: 113
Glucagon Regulation of Energy Expenditure
Maximilian Kleinert, Stephan Sachs, Kirk M. Habegger, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 21, pp. 5407-5407
Open Access | Times Cited: 107
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen, Brian Finan, Timo D. Müller, et al.
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 2, pp. 90-104
Closed Access | Times Cited: 104
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt, A. Götz, Matthias H. Tschöp, et al.
Peptides (2018) Vol. 100, pp. 190-201
Open Access | Times Cited: 100
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
David C. D. Hope, Matthew L. Vincent, Tricia Tan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 60
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Unnatural helical peptidic foldamers as protein segment mimics
Peng Sang, Jianfeng Cai
Chemical Society Reviews (2023) Vol. 52, Iss. 15, pp. 4843-4877
Open Access | Times Cited: 28
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Anna M. Puszkarska, Bruck Taddese, Jefferson D. Revell, et al.
Nature Chemistry (2024) Vol. 16, Iss. 9, pp. 1436-1444
Open Access | Times Cited: 11
Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
Jia Ying Cheang, Peter M. Moyle
ChemMedChem (2018) Vol. 13, Iss. 7, pp. 662-671
Closed Access | Times Cited: 71
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Seyed Ebrahim Alavi, Peter J. Cabot, Peter M. Moyle
Molecular Pharmaceutics (2019) Vol. 16, Iss. 6, pp. 2278-2295
Closed Access | Times Cited: 70
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Nathalia Romanelli Vicente Dragano, Johan Fernø, Carlos Diéguez, et al.
Neuroscience (2020) Vol. 437, pp. 215-239
Closed Access | Times Cited: 58
New Insights into the Structure and Function of Class B1 GPCRs
Brian P. Cary, Xin Zhang, Jianjun Cao, et al.
Endocrine Reviews (2022) Vol. 44, Iss. 3, pp. 492-517
Open Access | Times Cited: 35
Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant
Michelle Khai Khun Yap, Nurhamimah Misuan
Basic & Clinical Pharmacology & Toxicology (2018) Vol. 124, Iss. 5, pp. 513-527
Open Access | Times Cited: 56
Glucagon Control on Food Intake and Energy Balance
Omar Al–Massadi, Johan Fernø, Carlos Diéguez, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3905-3905
Open Access | Times Cited: 54
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Lotte Simonsen, Jesper Lau, Thomas Kruse, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0264974-e0264974
Open Access | Times Cited: 24
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations
Andreas Evers, Martin Bossart, Stefania Pfeiffer‐Marek, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 13, pp. 5580-5593
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top